![Hans Henskens](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenance du réseau au premier degré de Hans Henskens
Entité | Type d'entité | Industrie | |
---|---|---|---|
PharmaCell BV
![]() PharmaCell BV BiotechnologyHealth Technology PharmaCell BV manufactures cell therapy and regenerative medicine. The firm engages in human cell line development and manufacturing of bio pharmaceuticals. Its services include process research and development, project management, incoming logistics, incoming goods, manufacturing auto logous and allogeneic products, quality control, final formulation, release and outgoing logistics. The company was founded by René Lardenoije and Jan Thio in 2005 and is headquartered in Maastricht, the Netherlands.
5
| Subsidiary | Biotechnology | 5 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Hans Henskens via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
TIGENIX NV | Medical Specialties | Founder | |
DegenRx BV
![]() DegenRx BV BiotechnologyHealth Technology DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020. | Biotechnology | Corporate Officer/Principal | |
University of Groningen | College/University | Doctorate Degree | |
MENDUS AB | Biotechnology | Director/Board Member | |
DCPrime BV
![]() DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Synerkine Pharma BV
![]() Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Miscellaneous Commercial Services | Chief Executive Officer | |
Oxyrane UK Ltd.
![]() Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Rotterdam School of Management | College/University | Doctorate Degree | |
UNIQURE N.V. | Biotechnology | Chief Operating Officer | |
Abbott Healthcare Products BV
![]() Abbott Healthcare Products BV Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, Abbott Healthcare Products BV is a Dutch company that manufactures and distributes pharmaceuticals. The company is based in Weesp, Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal | |
DSM Biologics Holding, Inc.
![]() DSM Biologics Holding, Inc. BiotechnologyHealth Technology Part of DSM-Firmenich AG, DSM Biologics Holding, Inc. is a Canadian company that manufactures biological and pharmaceutical products. The private company is based in Montréal, Canada. The company was founded by Jos van Weperen. DSM Biologics Holding was acquired by DSM Pharmaceuticals, Inc., a subsidiary of DSM-Firmenich AG from Province of Québec on July 13, 2005. | Biotechnology | Chief Operating Officer | |
Brightlands Venture Partners BV
![]() Brightlands Venture Partners BV Investment ManagersFinance Brightlands Venture Partners is an independent regional venture capital firm headquartered in Brightlands, Netherlands. The firm was founded in 2004. | Investment Managers | Director/Board Member | |
Ghent University | College/University | Doctorate Degree | |
Kriya Materials BV
![]() Kriya Materials BV Industrial SpecialtiesProcess Industries Kriya Materials BV engages in the development and manufacture of anti-static coatings for plasma television. Its products include antistatic coatings, optical hard coat products, solar heat coatings, anti fouling hard coat and nano dispersion, and hard coat products. Its products are used in liquid crystal display plasma display, touch panels, and window film applications. The company was founded by Hugo Delissen, Edwin Currie, and Mark G. Tilley in 2006 and is headquartered in Geleen, the Netherlands. | Industrial Specialties | Director/Board Member | |
Indiana University | College/University | Undergraduate Degree | |
University of Tilburg | College/University | Undergraduate Degree | |
DSM Venturing BV
![]() DSM Venturing BV Investment ManagersFinance DSM Venturing BV (DSM Venturing) is the venture capital arm of Royal DSM NV in the Netherlands founded in 2001. DSM Venturing BV is headquartered in Geleen. | Investment Managers | Private Equity Investor | |
Neuroplast BV
![]() Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | Biotechnology | Director/Board Member | |
National Institutes of Health
![]() National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | General Government | Corporate Officer/Principal | |
Université Catholique de Louvain | College/University | Corporate Officer/Principal | |
Prometheus
![]() Prometheus Packaged SoftwareTechnology Services Prometheus is an independent network of four southern-European think tanks that specialize in economic, business, and geopolitical research. The private company is based in Antwerp, Belgium, and have subsidiaries in Belgium. Prometheus recently published a report on the music production and reproduction ecosystem. The Belgian company was founded in 2006 by Clyde Davis. | Packaged Software | Director/Board Member | |
Laboratory for Skeletal Development & Joint Disorders | Director/Board Member | ||
Universitaire Ziekenhuizen Leuven
![]() Universitaire Ziekenhuizen Leuven Hospital/Nursing ManagementHealth Services Universitaire Ziekenhuizen Leuven provides medical services. It offers abdominal surgery, abdominal transplant surgery and coordination, breast centre, cardiac surgery, dentistry, emergency medicine, endocrinology and haematology. The company was founded in 1080 and is headquartered in Leuven, Belgium. | Hospital/Nursing Management | Corporate Officer/Principal | |
Alloksys Life Sciences BV
![]() Alloksys Life Sciences BV Miscellaneous Commercial ServicesCommercial Services Alloksys Life Sciences BV provides therapies services. It offers Phase 3 clinical trials leading to registration of RESCAP (RESCuing Alkaline Phosphatase) for the prevention and treatment of ischemic injury and inflammation mediated complications in cardiothoracic surgery (APPIRED III). The company was founded by Ruud Brands in 2005 and is headquartered in Wageningen, the Netherlands. | Miscellaneous Commercial Services | Director/Board Member |
Statistiques
Internationale
Pays-Bas | 16 |
Belgique | 7 |
Etats-Unis | 3 |
Suède | 2 |
Royaume-Uni | 2 |
Sectorielle
Health Technology | 10 |
Consumer Services | 7 |
Commercial Services | 4 |
Finance | 4 |
Process Industries | 2 |
Opérationnelle
Director/Board Member | 15 |
Corporate Officer/Principal | 6 |
Doctorate Degree | 3 |
Private Equity Investor | 3 |
Chief Operating Officer | 3 |
Relations les plus connectées
- Bourse
- Insiders
- Hans Henskens
- Connexions Sociétés